Literature DB >> 32023582

Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy.

Hayato Tada1, Akihiro Nomura1,2, Kenichi Yoshimura2, Hiroshi Itoh3, Issei Komuro4, Masakazu Yamagishi5, Masayuki Takamura1, Masa-Aki Kawashiri1.   

Abstract

BACKGROUND: Few data specifically investigate associations between fasting/non-fasting triglycerides (TG) and cardiovascular (CV) events under statin therapy among Japanese diabetic patients.Methods and 
Results: We recruited 4,988 participants with diabetes from the EMPATHY study. Median follow-up was 3 years. We evaluated associations between serum fasting/non-fasting TG and first CV events in Cox-regression hazard models adjusted by classical risk factors. CV events were defined as (1) major adverse cardiac events (MACE) including myocardial infarction, stroke, or cardiac death; and (2) CV diseases (CVD) including myocardial infarction, unstable angina, ischemic stroke, or large artery disease or peripheral arterial disease. Fasting as well as non-fasting TG were associated with MACE (adjusted hazard ratio [HR]: 1.017 per 10 mg/dL; 95% confidence interval [CI]: 1.000-1.037; P=0.046, adjusted HR: 1.028 per 10 mg/dL; 95% CI: 1.006-1.050; P=0.0091) and CVD (adjusted HR: 1.024 per 10 mg/dL; 95% CI: 1.011-1.038; P=4.4×10-3, adjusted HR: 1.028 per 10 mg/dL; 95% CI: 1.010-1.046; P=4.9×10-3). Comparing the top quartile with the bottom quartile of non-fasting TG, adjusted HR significantly increased 5.18 (95% CI: 1.38-18.3, P=0.014) for MACE, and 2.40 (95% CI: 1.11-4.75, P=0.021) for CVD, while adjusted HR did not change when divided into quartile of fasting TG.
CONCLUSIONS: Non-fasting TG could be considered as a substitute for fasting TG as a risk stratification for future CV events among Japanese diabetic patients.

Entities:  

Keywords:  Cardiovascular disease; Residual risk; Statins; Triglycerides

Mesh:

Substances:

Year:  2020        PMID: 32023582     DOI: 10.1253/circj.CJ-19-0981

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  7 in total

1.  Small Dense Low-Density Lipoprotein Cholesterol is a Potential Marker for Predicting Laser Treatment for Retinopathy in Diabetic Patients.

Authors:  Atsuko Nakayama; Hiroyuki Morita; Tatsuyuki Sato; Takuya Kawahara; Norifumi Takeda; Satoshi Kato; Hiroshi Itoh; Issei Komuro
Journal:  J Atheroscler Thromb       Date:  2021-05-14       Impact factor: 4.394

Review 2.  Hypertriglyceridemia: A Neglected Risk Factor for Ischemic Stroke?

Authors:  Hai-Jie Liang; Qing-Yi Zhang; Yi-Tong Hu; Guo-Qing Liu; Rong Qi
Journal:  J Stroke       Date:  2022-01-31       Impact factor: 6.967

Review 3.  Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review.

Authors:  Radu Sascău; Alexandra Clement; Rodica Radu; Cristina Prisacariu; Cristian Stătescu
Journal:  Nutrients       Date:  2021-05-22       Impact factor: 5.717

4.  Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults.

Authors:  Yuanli Dong; Xukui Liu; Yingxin Zhao; Qiang Chai; Hua Zhang; Yumei Gao; Zhendong Liu
Journal:  Front Cardiovasc Med       Date:  2021-06-17

5.  Thresholds for postprandial hyperglycemia and hypertriglyceridemia associated with increased mortality risk in type 2 diabetes patients: A real-world longitudinal study.

Authors:  Toshiko Takao; Machi Suka; Hiroyuki Yanagisawa; Masato Kasuga
Journal:  J Diabetes Investig       Date:  2020-10-20       Impact factor: 4.232

6.  The Effect of Diet on Cardiovascular Disease, Heart Disease, and Blood Vessels.

Authors:  Hayato Tada; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  Nutrients       Date:  2022-01-07       Impact factor: 5.717

7.  Triglycerides on the Rise!

Authors:  Hayato Tada; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Atheroscler Thromb       Date:  2021-06-02       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.